- Bora Pharmaceuticals is adding liquid-filled hard capsule (LFC) manufacturing capabilities at its Zhunan, Taiwan, facility, targeting Q1 2026 for commercial availability.
- The expansion enhances the company’s oral solid dose technology, supporting high-potency formulations and advanced drug delivery for oncology and complex compounds.
Bora Pharmaceuticals has announced the introduction of liquid-filled hard capsule (LFC) manufacturing at its Zhunan, Taiwan, facility. The expansion is part of the company’s strategy to strengthen its oral solid dose portfolio and support high-potency and advanced delivery formulations. The new operational area is expected to be fully available for clients in the first quarter of 2026.
The Zhunan site, approved by the USFDA and MHRA, currently supplies products to the United States, Taiwan, and other Asian markets. The facility will now support stable delivery of sensitive compounds, including oncology and potent drugs, reflecting growing industry demand for more complex pharmaceutical ingredients.
“This investment reiterates Bora’s commitment to innovation, infrastructure, and long-term growth. By adding liquid capsule manufacturing, we are equipping our partners with optimized formulation that reduces delays and accelerates commercialization.”
J.D. Mowery, president of Bora’s CDMO Business.
The company highlights the commercial potential of LFCs, noting the global liquid capsule supplements market is projected to reach $9.1 billion by 2033. LFCs are increasingly preferred for their enhanced absorption rates and ability to handle complex formulations compared with other oral delivery options.
Bora’s Zhunan site is one of seven cGMP facilities worldwide, delivering products to over 100 countries. The site’s on-time, in-full delivery record underscores Bora’s position as a reliable CDMO partner, providing secure and consistent global supply to its clients.
